Skip to main content

Table 2 Accumulation of 64 Cu-DOTA-trastuzumab in brain tumor

From: 64Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients

Patient number Lesion number Location SUVmax (tumor/BG) TNR
24 h 48 h 24 h 48 h
1 1 Rt-cerebellum 1.4/0.2 2.1/0.2 9.3 12.5
  2 Rt-cerebellum 1.3/0.2 2.1/0.2 8.7 12.4
  3 Vermis 1.4/0.2 2.1/0.2 9.1 12.4
  4 Lt-cerebellum 1.1/0.2 1.6/0.2 7.1 11.8
2 5 Lt-cerebellum 1.2/0.1 2.1/0.2 8.2 12.2
3 6 Lt-frontal 0.7/0.2 1.0/0.2 4.1 5.5
  7 Lt-frontal 0.6/0.2 0.7/0.2 3.3 4.1
4 8 Lt-frontal 0.9/0.2 1.6/0.2 5.8 9.2
  9 Rt-cerebellum 0.8/0.2 1.2/0.2 5.1 7.8
5 10 Lt-cerebellum 1.1/0.2 NA/NA 6.1 NA
  1. 64Cu-DOTA-trastuzumab PET imaging at 48 h after injection was not carried out because of surgical resection.
  2. BG, background; NA, inpatient no. 5.